A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes

BACKGROUND: The once-daily glucagon-like peptide 1 (GLP-1) analogue, liraglutide has been shown to reduce major adverse cardiovascular events (MACE) and progression of chronic kidney disease (CKD). The once-weekly GLP-1 analogue, semaglutide also reduced MACE and renal events. Based on the evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanai, Hidekatsu, Hakoshima, Mariko, Adachi, Hiroki, Katsuyama, Hisayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635779/
https://www.ncbi.nlm.nih.gov/pubmed/36405226
http://dx.doi.org/10.14740/cr1441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635779/
https://www.ncbi.nlm.nih.gov/pubmed/36405226
http://dx.doi.org/10.14740/cr1441

Ejemplares similares